Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Liposomal Doxorubicin Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Liposomal Doxorubicin Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Intravenous Infusion
      • 1.3.3 Injection
    • 1.4 Market Segment by Application
      • 1.4.1 Global Liposomal Doxorubicin Market Share by Application (2019-2025)
      • 1.4.2 Academic
      • 1.4.3 Hospitals
      • 1.4.4 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Liposomal Doxorubicin Market Size
      • 2.1.1 Global Liposomal Doxorubicin Revenue 2014-2025
      • 2.1.2 Global Liposomal Doxorubicin Sales 2014-2025
    • 2.2 Liposomal Doxorubicin Growth Rate by Regions
      • 2.2.1 Global Liposomal Doxorubicin Sales by Regions 2014-2019
      • 2.2.2 Global Liposomal Doxorubicin Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Liposomal Doxorubicin Sales by Manufacturers
      • 3.1.1 Liposomal Doxorubicin Sales by Manufacturers 2014-2019
      • 3.1.2 Liposomal Doxorubicin Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Liposomal Doxorubicin Revenue by Manufacturers (2014-2019)
      • 3.2.2 Liposomal Doxorubicin Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Liposomal Doxorubicin Market Concentration Ratio (CR5 and HHI)
    • 3.3 Liposomal Doxorubicin Price by Manufacturers
    • 3.4 Key Manufacturers Liposomal Doxorubicin Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Liposomal Doxorubicin Market
    • 3.6 Key Manufacturers Liposomal Doxorubicin Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Intravenous Infusion Sales and Revenue (2014-2019)
      • 4.1.2 Injection Sales and Revenue (2014-2019)
    • 4.2 Global Liposomal Doxorubicin Sales Market Share by Type
    • 4.3 Global Liposomal Doxorubicin Revenue Market Share by Type
    • 4.4 Liposomal Doxorubicin Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Liposomal Doxorubicin Sales by Application

    6 United States

    • 6.1 United States Liposomal Doxorubicin Breakdown Data by Company
    • 6.2 United States Liposomal Doxorubicin Breakdown Data by Type
    • 6.3 United States Liposomal Doxorubicin Breakdown Data by Application

    7 European Union

    • 7.1 European Union Liposomal Doxorubicin Breakdown Data by Company
    • 7.2 European Union Liposomal Doxorubicin Breakdown Data by Type
    • 7.3 European Union Liposomal Doxorubicin Breakdown Data by Application

    8 China

    • 8.1 China Liposomal Doxorubicin Breakdown Data by Company
    • 8.2 China Liposomal Doxorubicin Breakdown Data by Type
    • 8.3 China Liposomal Doxorubicin Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Liposomal Doxorubicin Breakdown Data by Company
    • 9.2 Rest of World Liposomal Doxorubicin Breakdown Data by Type
    • 9.3 Rest of World Liposomal Doxorubicin Breakdown Data by Application
    • 9.4 Rest of World Liposomal Doxorubicin Breakdown Data by Countries
      • 9.4.1 Rest of World Liposomal Doxorubicin Sales by Countries
      • 9.4.2 Rest of World Liposomal Doxorubicin Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Johnson & Johnson
      • 10.1.1 Johnson & Johnson Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Liposomal Doxorubicin
      • 10.1.4 Liposomal Doxorubicin Product Introduction
      • 10.1.5 Johnson & Johnson Recent Development
    • 10.2 Pfizer
      • 10.2.1 Pfizer Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Liposomal Doxorubicin
      • 10.2.4 Liposomal Doxorubicin Product Introduction
      • 10.2.5 Pfizer Recent Development
    • 10.3 Sun Pharmaceutical
      • 10.3.1 Sun Pharmaceutical Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Liposomal Doxorubicin
      • 10.3.4 Liposomal Doxorubicin Product Introduction
      • 10.3.5 Sun Pharmaceutical Recent Development
    • 10.4 Cadila Pharmaceuticals
      • 10.4.1 Cadila Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Liposomal Doxorubicin
      • 10.4.4 Liposomal Doxorubicin Product Introduction
      • 10.4.5 Cadila Pharmaceuticals Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Liposomal Doxorubicin Sales Channels
      • 11.2.2 Liposomal Doxorubicin Distributors
    • 11.3 Liposomal Doxorubicin Customers

    12 Market Forecast

    • 12.1 Global Liposomal Doxorubicin Sales and Revenue Forecast 2019-2025
    • 12.2 Global Liposomal Doxorubicin Sales Forecast by Type
    • 12.3 Global Liposomal Doxorubicin Sales Forecast by Application
    • 12.4 Liposomal Doxorubicin Forecast by Regions
      • 12.4.1 Global Liposomal Doxorubicin Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Liposomal Doxorubicin Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.
      In North America, the highest incidence of sarcoma, ovarian cancer, breast and liver cancer, and several other cancers is the highest. North America has become a major market due to the existence of advanced healthcare facilities and a high level of patient awareness of the various available treatments.
      In 2019, the market size of Liposomal Doxorubicin is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Liposomal Doxorubicin.

      This report studies the global market size of Liposomal Doxorubicin, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Liposomal Doxorubicin sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Johnson & Johnson
      Pfizer
      Sun Pharmaceutical
      Cadila Pharmaceuticals
      ...

      Market Segment by Product Type
      Intravenous Infusion
      Injection

      Market Segment by Application
      Academic
      Hospitals
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Liposomal Doxorubicin status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Liposomal Doxorubicin manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Liposomal Doxorubicin are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now